よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (55 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
145. Lovleva A, et al. Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals:
Diversification of Circulating Lineages and Antimicrobial Resistance. mBio. 2022.
26;13(2):e0275921.
4
5
6
146. Uechi K, et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin
Microbiol. 2017. 55(12):3405-3410.
7
8
9
10
147. Khoo BY, et al. Evaluation of NG-Test CARBA 5 version 2, Cepheid Xpert Carba-R, and
carbapenem inactivation methods in comparison to whole-genome sequencing for the
identification of carbapenemases in non-fermenting Gram-negative bacilli. J Clin
Microbiol. 2023. 61(9):e0031623.
11
12
13
148. Wisplinghoff H, et al. Nosocomial bloodstream infections caused by Acinetobacter
species in United States hospitals: clinical features, molecular epidemiology, and
antimicrobial susceptibility. Clin Infect Dis. 2000. 31(7):690-697.
14
15
16
149. Martin-Aspas A, et al. Differential characteristics of Acinetobacter baumannii colonization
and infection: risk factors, clinical picture, and mortality. Infect Drug Resist. 2018.
11:861-872.
17
18
150. Richards GA, et al. The challenges of difficult-to-treat Acinetobacter infections. Clin
Microbiol Rev. 2024. 37(4):e0009324.
19
20
151. Fishbain J, et al. Treatment of Acinetobacter infections. Clin Infect Dis. 2010. 51(1):7984.
21
22
23
152. Chang YY, et al. Comparison of Cefepime-Cefpirome and Carbapenem Therapy for
Acinetobacter Bloodstream Infection in a Multicenter Study. Antimicrob Agents
Chemother. 2020. 64(6):e02392-19.
24
25
26
153. Penwell WF, et al. Molecular mechanisms of sulbactam antibacterial activity and
resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother.
2015. 59(3):1680-1689.
27
28
154. Isler B, et al. New Treatment Options against Carbapenem-Resistant Acinetobacter
baumannii Infections. Antimicrob Agents Chemother. 2019. 63(1):e01110-18.
29
155. https://www.kegg.jp/medicus-bin/japic_med?japic_code=00071080
30
31
32
156. Abouelhassan Y, et al. Ampicillin-sulbactam against Acinetobacter baumannii infections:
pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and
dosing recommendations. J Antimicrob Chemother. 2024. 79(9):2227-2236.
33
34
157. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
35
36
37
38
158. Fernández-Cuenca F, et al. Spanish Society of Clinical Microbiology and Infectious
Diseases (SEIMC). Reporting antimicrobial susceptibilities and resistance phenotypes in
Acinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother. 2018.
73(3):692-697.
39
40
159. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
41
42
160. Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant
Acinetobacter infections. Clin Infect Dis. 2014. 59 Suppl 6:S374-80.
43
44
45
161. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
55
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
145. Lovleva A, et al. Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals:
Diversification of Circulating Lineages and Antimicrobial Resistance. mBio. 2022.
26;13(2):e0275921.
4
5
6
146. Uechi K, et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin
Microbiol. 2017. 55(12):3405-3410.
7
8
9
10
147. Khoo BY, et al. Evaluation of NG-Test CARBA 5 version 2, Cepheid Xpert Carba-R, and
carbapenem inactivation methods in comparison to whole-genome sequencing for the
identification of carbapenemases in non-fermenting Gram-negative bacilli. J Clin
Microbiol. 2023. 61(9):e0031623.
11
12
13
148. Wisplinghoff H, et al. Nosocomial bloodstream infections caused by Acinetobacter
species in United States hospitals: clinical features, molecular epidemiology, and
antimicrobial susceptibility. Clin Infect Dis. 2000. 31(7):690-697.
14
15
16
149. Martin-Aspas A, et al. Differential characteristics of Acinetobacter baumannii colonization
and infection: risk factors, clinical picture, and mortality. Infect Drug Resist. 2018.
11:861-872.
17
18
150. Richards GA, et al. The challenges of difficult-to-treat Acinetobacter infections. Clin
Microbiol Rev. 2024. 37(4):e0009324.
19
20
151. Fishbain J, et al. Treatment of Acinetobacter infections. Clin Infect Dis. 2010. 51(1):7984.
21
22
23
152. Chang YY, et al. Comparison of Cefepime-Cefpirome and Carbapenem Therapy for
Acinetobacter Bloodstream Infection in a Multicenter Study. Antimicrob Agents
Chemother. 2020. 64(6):e02392-19.
24
25
26
153. Penwell WF, et al. Molecular mechanisms of sulbactam antibacterial activity and
resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother.
2015. 59(3):1680-1689.
27
28
154. Isler B, et al. New Treatment Options against Carbapenem-Resistant Acinetobacter
baumannii Infections. Antimicrob Agents Chemother. 2019. 63(1):e01110-18.
29
155. https://www.kegg.jp/medicus-bin/japic_med?japic_code=00071080
30
31
32
156. Abouelhassan Y, et al. Ampicillin-sulbactam against Acinetobacter baumannii infections:
pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and
dosing recommendations. J Antimicrob Chemother. 2024. 79(9):2227-2236.
33
34
157. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
35
36
37
38
158. Fernández-Cuenca F, et al. Spanish Society of Clinical Microbiology and Infectious
Diseases (SEIMC). Reporting antimicrobial susceptibilities and resistance phenotypes in
Acinetobacter spp: a nationwide proficiency study. J Antimicrob Chemother. 2018.
73(3):692-697.
39
40
159. Piperaki ET, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an
effective treatment. Clin Microbiol Infect. 2019. 25(8):951-957.
41
42
160. Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant
Acinetobacter infections. Clin Infect Dis. 2014. 59 Suppl 6:S374-80.
43
44
45
161. Kengkla K, et al. Comparative efficacy and safety of treatment options for MDR and
XDR Acinetobacter baumannii infections: a systematic review and network metaanalysis. J Antimicrob Chemother. 2018. 73(1):22-32.
55